Esperion Therapeutics (ESPR) Accounts Payables (2012 - 2026)

Esperion Therapeutics has reported Accounts Payables for 15 years, with the latest figure at $68.4 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables fell 4.98% year-over-year to $68.4 million; the trailing twelve-month figure through Mar 2026 stood at $68.4 million (down 4.98% YoY), and the FY2025 full-year result was $65.1 million, up 25.98% from the prior year.
• Accounts Payables for Q1 2026 stood at $68.4 million, up from $65.1 million in the prior quarter.
• The five-year high for Accounts Payables was $77.5 million in Q3 2025, with the low at $12.8 million in Q2 2022.
• Historically, Accounts Payables has averaged $41.2 million across 5 years, with a median of $31.7 million in 2023.
• Annual changes were most pronounced in 2022 — Accounts Payables tumbled 56.28% — and 2025, when it jumped 153.21%.
• Esperion Therapeutics' Accounts Payables stood at $23.0 million in 2022, then soared by 37.66% to $31.7 million in 2023, then soared by 62.84% to $51.6 million in 2024, then climbed by 25.98% to $65.1 million in 2025, then climbed by 5.13% to $68.4 million in 2026.
• The last three Accounts Payables figures came in at $68.4 million (Q1 2026), $65.1 million (Q4 2025), and $77.5 million (Q3 2025), per Business Quant data.